Noskapin Orifarm Healthcare (Noscapine Hydrochloride)

Noscapine Hydrochloride, the active ingredient in Noskapin Orifarm Healthcare, is an antitussive presented as an oral dosage form for oral use. Originating from the European Union market, this over‑the‑counter product suppresses non‑productive coughs in adults and children by acting centrally on the cough reflex, offering symptomatic relief without significant sedation.

GNH USA supplies Noskapin Orifarm Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches meet EU pharmacopeial specifications and are shipped under controlled conditions to ensure product integrity.

Noskapin (noscapine hydrochloride) is an antitussive that acts on the central cough pathway. - Non‑productive cough: reduces cough frequency and intensity in patients with dry cough. - Cough due to upper respiratory tract infection: provides symptomatic relief during viral colds. - Cough associated with bronchitis: helps alleviate persistent dry cough in acute bronchitis.

Noskapin may cause adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Dizziness - Headache - Dry mouth

Serious or Rare Side Effects: - Allergic reactions (rash, urticaria, angioedema) - Hepatotoxicity (elevated liver enzymes).

Before using Noskapin, consider the following precautions. - Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown; weigh potential risks against benefits. - Renal impairment: no dosage adjustment required, but monitor severe cases. - Hepatic impairment: use with caution and monitor liver function. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original container, protect from moisture and light.

Noskapin can interact with other medicines; review the following categories.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of additive central nervous system effects. - CNS depressants (e.g., opioids, benzodiazepines): may enhance sedation.

Moderate Interactions (Monitor Closely): - Alcohol: may increase dizziness. - CYP450 substrates: noscapine may inhibit certain enzymes; monitor plasma levels. - Anticholinergic agents: may exacerbate dry mouth.